Nicholas Investment Partners, LP Tg Therapeutics, Inc. Transaction History

Nicholas Investment Partners, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$3.74 - $10.66 $482,647 - $1.38 Million	-129,050 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$7.81 - $20.45 $1.22 Million - $3.21 Million	-156,759 Reduced 54.85%	129,050 $1.23 Million
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $3.04 Million - $7.1 Million	-200,029 Reduced 41.17%	285,809 $5.43 Million
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $3.81 Million - $7.08 Million	-175,126 Reduced 26.5%	485,838 $16.2 Million
Q2 2021 Aug 10, 2021	BUY	$32.5 - $48.96 $1.14 Million - $1.72 Million	35,177 Added 5.62%	660,964 $25.6 Million
Q1 2021 May 14, 2021	SELL	$41.61 - $54.3 $99,239 - $129,505	-2,385 Reduced 0.38%	625,787 $30.2 Million
Q4 2020 Feb 11, 2021	BUY	$25.27 - $54.9 $10.1 Million - $21.9 Million	398,720 Added 173.77%	628,172 $32.7 Million
Q3 2020 Nov 13, 2020	BUY	$18.49 - $27.24 $4.24 Million - $6.25 Million	229,452 New	229,452 $6.14 Million

287

91.8M

1.9M

1.45M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.46B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.